Peregrine Ventures is pleased to welcome Merck as a new strategic partner in the Incentive technological incubator, operated under license from the Israel Innovation Authority.
Incentive, based in Or Yehuda and managed by Peregrine since 2002, has supported the formation and growth of more than 60 companies, including Valtech, CartiHeal, and CardioValve—each reaching significant commercial milestones.
Merck, a global science and technology company, joins a consortium that backs early-stage innovation in bio-convergence, pharmaceuticals, and biotechnology. The collaboration provides Merck with early access to promising startups, alongside opportunities to support product development, early-phase trials, and regulatory planning.
Other members of the consortium include Becton Dickinson (BD), Bristol-Myers Squibb (BMS), Elbit Systems, Shaare Zedek Medical Center, Tel Aviv University, and Ben-Gurion University. Together, these partners represent a diverse and experienced group of academic and industry leaders working to advance next-generation health technologies from their earliest stages.
For startups, Merck’s participation brings additional pathways for scientific collaboration, strategic alignment, and global scale. This partnership reinforces Incentive’s mission to support high-impact ventures through capital, expertise, and a strong support ecosystem.
